Diamedica Therapeutics INC Form 4 insider transactions

Director Randall Michael Giuffre was granted 40,412 stock options in DiaMedica Therapeutics Inc. on June 1, 2026.

Director Richard Kuntz was granted 40,412 stock options in DiaMedica Therapeutics Inc. as part of his compensation.

DiaMedica Therapeutics Inc. Director Daniel J. O'Connor was granted 40,412 stock options with an exercise price of $5.84, vesting quarterly.

DiaMedica Therapeutics Inc. Director Tanya Lewis was granted 40,412 stock options with an exercise price of $5.84, vesting quarterly.

DiaMedica Therapeutics Inc. director Charles Pauling Semba was granted 40,412 stock options with an exercise price of $5.84, vesting quarterly.

Director James T. Parsons of DiaMedica Therapeutics Inc. has filed a Form 4, reporting a transaction related to stock options.

DiaMedica Therapeutics Inc. reports the grant of a significant stock option to President & CEO Dietrich John Pauls, exercisable at $5.84.

DiaMedica Therapeutics Inc. reports that CFO Scott Kellen was granted stock options for 162,000 shares with an exercise price of $5.84, vesting over four years.

DiaMedica Therapeutics reports a stock option grant to Chief Medical Officer Julie Krop, with vesting over four years.

DiaMedica Therapeutics Inc. Director James T. Parsons acquired 10,095 shares of common stock through a deferred stock unit grant in lieu of cash retainer fees.

DiaMedica Therapeutics Director Randall Michael Giuffre acquired 6,175 shares of common stock through a deferred stock unit settlement, part of a pre-arranged plan.

DiaMedica Therapeutics Inc. Director Charles Pauling Semba acquired 3,355 shares of common stock through the settlement of restricted stock units, increasing his beneficial ownership to 47,963 shares.

DiaMedica Therapeutics director and 10% owner Jan Stahlberg, through Trill AB, significantly increased his beneficial ownership by purchasing over 1 million common shares in November 2025.

DiaMedica Therapeutics Director James T. Parsons exercised 12,000 stock options, increasing his direct beneficial ownership to 87,854 common shares.

DiaMedica Therapeutics Inc.'s Chief Marketing Officer, Julie Krop, was granted 450,000 stock options with an exercise price of $4.58.

DiaMedica Therapeutics director and 10% owner Jan Stahlberg, through Trill AB, significantly increased his beneficial ownership of common shares in August 2025.

DiaMedica Therapeutics Inc. saw a significant increase in insider ownership as Director and 10% owner Jan Stahlberg, through Trill AB, acquired over 1.5 million common shares for approximately $5.4 million.

Thomas Von Koch, a Director and 10% owner of DiaMedica Therapeutics Inc., significantly increased his indirect beneficial ownership by purchasing 2,857,142 common shares.

DiaMedica Therapeutics Inc. Director and 10% owner Richard Jacinto II has disclosed a planned acquisition of 400,000 common shares at $3.50 each, scheduled for July 23, 2025, under a Rule 10b5-1 plan.

DiaMedica Therapeutics Inc.'s Chief Business Officer, David J. Wambeke, was granted 250,000 stock options with an exercise price of $4.11, vesting over four years.

A director at DiaMedica Therapeutics Inc., Charles Pauling Semba, has reported the acquisition of stock options and restricted stock units, increasing his beneficial ownership in the company.

DiaMedica Therapeutics Inc.'s President and CEO, Pauls Dietrich John, was granted 600,000 stock options at an exercise price of $4.11, aligning executive incentives with shareholder value.

DiaMedica Therapeutics Inc. Director James T. Parsons acquired 40,739 stock options and reported beneficial ownership of 75,854 common shares, signaling increased alignment with shareholder interests.

DiaMedica Therapeutics Inc. Director Tanya Lewis has acquired 32,162 stock options with an exercise price of $4.11, vesting over one year.

DiaMedica Therapeutics Director Richard Kuntz has reported the grant of 32,162 stock options with an exercise price of $4.11 and updated his beneficial ownership of common shares to 24,210, including restricted stock units.

DiaMedica Therapeutics Inc.'s CFO and Secretary, Scott Kellen, was granted 225,000 stock options with an exercise price of $4.11, alongside his existing direct ownership of 32,290 common shares.

DiaMedica Therapeutics Inc. Director Randall Michael Giuffre has reported the acquisition of 32,162 stock options with an exercise price of $4.11, alongside his updated beneficial ownership of common shares.

Director Richard D. Pilnik exercised stock options to acquire 24,000 shares of DiaMedica Therapeutics Inc. common stock at $2.11 per share.

Director Daniel J. O'Connor acquired stock options in DiaMedica Therapeutics, vesting over three years.

Director Randall Michael Giuffre exercised stock options at DiaMedica Therapeutics, increasing his direct and indirect beneficial ownership of voting common shares.